New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
11:34 EDTVIVOMeridian receives Canadian licenses for two illumigene platforms
Meridian Bioscience announced that it has received medical device license approval from Health Canada to market two additional assays for use on their illumigene molecular diagnostic platform. With the addition of illumigene Mycoplasma and illumigene Pertussis, Meridian continues to expand its position in the Canadian market by providing innovative testing solutions that meet the needs of the clinical laboratory and drive improvements in patient care.
News For VIVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2015
08:02 EDTVIVOMeridian Bioscience reaffirms FY15 EPS view 85c-91c, consensus 86c
Subscribe for More Information
08:02 EDTVIVOMeridian Bioscience reports Q3 EPS 22c, consensus 22c
Reports Q3 revenue $48.2M, consensus $48.6M.
July 20, 2015
09:26 EDTVIVOMeridican says illumigene receives FDA clearance
Meridian Bioscience announced that it has received FDA clearance for two new molecular assays for the detection of Herpes Simplex Virus Type 1 and Type 2, to be run on its illumigene molecular platform. The illumigene HSV 1&2 assays, launched earlier this year in Europe, are now available immediately in the U.S.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use